지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Lenalidomide, an orally administered immune-modulating drug, has several mechanisms of action against multiple myeloma(MM). However, the mechanisms of action of immune-modulating drugs are not understood completely. Lenalidomidemaintenance therapy prolongs the time to progression and increases the overall survival in patients with MM. However, secondaryprimary malignancy (SPM) has been noted as a serious adverse event in patients with MM treated with lenalidomide. Lenalidomidetreatment is not covered by insurance. Consequently, physicians have little experience with the adverse events of lenalidomidetreatment in patients with MM. Here, we describe a case of breast cancer after lenalidomide treatment for MM. To our knowledge,this is the first report of a lenalidomide-associated SPM in Korea. The risk factors associated with lenalidomide-associated SPMshould be considered carefully when implementing chemotherapy regimens in patients with MM.
목차
등록된 정보가 없습니다.
참고문헌 (9)
참고문헌 신청
Attal M / 2010 / Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02 / Blood 116 : 310 ~
Dimopoulos MA / 2012 / A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide / Blood 119 : 2764 ~ 2767
Latif T / 2012 / Thalidomide and its analogues in the treatment of Multiple Myeloma / Exp Hematol Oncol 1 : 27 ~
McCarthy PL / 2009 / Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple mye
McCarthy PL / 2010 / Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT)
Dimopoulos MA / 2012 / A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide / Blood 119 : 2764 ~ 2767
Latif T / 2012 / Thalidomide and its analogues in the treatment of Multiple Myeloma / Exp Hematol Oncol 1 : 27 ~
McCarthy PL / 2009 / Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple mye
McCarthy PL / 2010 / Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT)
이 논문의 저자 정보
최근 본 자료
댓글(0)
0